drugset / Trial / NCT03127345

Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health

NCT03127345

Phase 2 Withdrawn Boston Children's Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized clinical trial comparing Omegaven® treatment with standard of care (soybean-based lipid formulation, Intralipid®) on bone health outcomes in infants with esophageal atresia (EA) undergoing surgical repair at Boston Children's Hospital.

Timeline

Start
2019-09
Primary completion
2023-09
Completion
2023-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Intralipid Other / unclassified
Subject Omegaven Other / unclassified 1 g/kg Intravenous

Indications